AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20098527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 737
Study 20098640 — intervention group
Group type: EXPERIMENTAL
Intervention: self-help booklet with telephone support from a vestibular therapist
Number of subjects: 330
Study 20098640 — intervention group
Group type: EXPERIMENTAL
Intervention: self-help booklet alone
Number of subjects: 330
Study 20098640 — intervention group
Group type: COMPARATOR
Intervention: routine medical care
Number of subjects: 330
Study 20098694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone (BMS-247550) at a dose of 20 mg/m(2) on days 1, 8, and 15 during each 28-day cycle
Number of subjects: 24
Study 20098694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone (BMS-247550)
Number of subjects: 24
Study 20100797 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 315
Study 20100797 — intervention group
Group type: EXPERIMENTAL
Intervention: BASDAI clinical response
Number of subjects: 315
Study 20100797 — intervention group
Group type: EXPERIMENTAL
Intervention: ASQOL quality of life response
Number of subjects: 315
Study 20100797 — intervention group
Group type: EXPERIMENTAL
Intervention: Absenteeism
Number of subjects: 315
Study 20100797 — intervention group
Group type: EXPERIMENTAL
Intervention: WPAI:SpA
Number of subjects: 315
Study 20101385 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow blood autotransplantation
Number of subjects: 0
Study 20101893 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant methionyl human leptin (initiated at baseline, evaluated at 2 weeks and 6 weeks)
Number of subjects: 1
Study 20101893 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements (before treatment)
Number of subjects: 1
Study 20102271 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of minority Y181C mutants in adherent patients
Number of subjects: 195
Study 20102271 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of minority Y181C mutants in nonadherent patients
Number of subjects: 195
Study 20102271 — intervention group
Group type: EXPERIMENTAL
Intervention: Minority Y181C variants
Number of subjects: 195
Study 20102281 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFN-alpha-2a/ribavirin
Number of subjects: 70
Study 20102307 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 0
Study 20102307 — intervention group
Group type: COMPARATOR
Intervention: Control (Inhaled bronchodilators)
Number of subjects: 0
Study 20102607 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the NVOG guideline and MOET-instructions
Number of subjects: 320
Study 20102607 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored strategy to implement the NVOG guideline and MOET-instructions
Number of subjects: 320
Study 20102607 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with 30 professionals and 10 patients
Number of subjects: 320
Study 20102607 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire study among all Dutch gynaecologists and midwives
Number of subjects: 320
Study 20106720 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant capecitabine and oxaliplatin (oxaliplatin 130 mg/m2 on day 1 with capecitabine 1000 mg/m2 twice daily for 14 days every 3 weeks) followed by chemoradiotherapy (54 Gy over 6 weeks) with capecitabine (825 mg/m2 twice daily) and total mesorectal excision.
Number of subjects: 105
Study 20106720 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 105
Study 20107214 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of live, oral rotavirus vaccine
Number of subjects: 4939
Study 20107214 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of live, oral rotavirus vaccine
Number of subjects: 4939
Study 20107214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4939
Study 20107214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled vaccine group (two or three doses of vaccine)
Number of subjects: 4939
Study 20107214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled vaccine group
Number of subjects: 4939
Study 20107229 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8(+) T cells capable of secreting interferon-gamma (IFN-gamma) detected at 8 weeks after transplantation
Number of subjects: 0
Study 20107229 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery of CD4(+)CD45RA(+) T cells and reconstitution of thymopoiesis
Number of subjects: 0
Study 20107229 — intervention group
Group type: EXPERIMENTAL
Intervention: Attainment of T-cell receptor rearrangement excision circle (TREC) levels of 2000 or more copies/mug DNA
Number of subjects: 0
Study 20109568 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCs from third party unrelated donors
Number of subjects: 20
Study 20109568 — intervention group
Group type: COMPARATOR
Intervention: HLA-mismatched PBSCs without MSCs (historic control)
Number of subjects: 20
Study 20110053 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 200 mg (single oral dose)
Number of subjects: 27
Study 20111582 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVAX (0.2 mg)
Number of subjects: 45
Study 20111582 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVAX (1.0 mg)
Number of subjects: 45
Study 20111582 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVAX (4.0 mg)
Number of subjects: 45
Study 20111582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 20111582 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVAX
Number of subjects: 45
Study 20112079 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gabapentin 600 mg administered 90 min prior to induction of anesthesia, then every eight hours for a total of four doses
Number of subjects: 16
Study 20112381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 2 mg/kg
Number of subjects: 16
Study 20112381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg
Number of subjects: 16
Study 20112381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg
Number of subjects: 16
Study 20112381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (all dosages)
Number of subjects: 16
Study 20113458 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SPOT.TB test
Number of subjects: 209
Study 20113458 — intervention group
Group type: COMPARATOR
Intervention: TST >= 5 mm
Number of subjects: 209
Study 20113458 — intervention group
Group type: COMPARATOR
Intervention: TST >= 10 mm
Number of subjects: 209
Study 20113458 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate T-SPOT.TB test
Number of subjects: 209
Study 20113458 — intervention group
Group type: COMPARATOR
Intervention: T-SPOT.TB test vs TST
Number of subjects: 209
Study 20113458 — intervention group
Group type: COMPARATOR
Intervention: Induration size of TST
Number of subjects: 209
Study 20113458 — intervention group
Group type: COMPARATOR
Intervention: Clinical risk for LTBI
Number of subjects: 209
Study 20117459 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 14
Study 20119473 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of care (POC) urine drug testing
Number of subjects: 1000
Study 20119473 — intervention group
Group type: COMPARATOR
Intervention: Liquid chromatography tandem mass spectroscopy (LC/MS/MS)
Number of subjects: 1000
Study 20121884 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE epsilon4 and ACE D alleles
Number of subjects: 0
Study 20121884 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoglycaemic events or high HbA(1c)
Number of subjects: 0
Study 20124123 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting smoking
Number of subjects: 18809
Study 20124123 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to diet and exercise
Number of subjects: 18809
Study 20124123 — intervention group
Group type: COMPARATOR
Intervention: Persistent smoking and nonadherence to diet and exercise
Number of subjects: 18809
Study 20124511 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (50 mg/kg/d on days 3 and 4 after transplantation)
Number of subjects: 117
Study 20124586 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES) - 'off-label' use
Number of subjects: 2067
Study 20124586 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES) - 'on-label' use
Number of subjects: 2067
Study 20124586 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES) - in diabetics
Number of subjects: 2067
Study 20126394 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA/rAd5 prime-boost regimen
Number of subjects: 0
Study 20126394 — intervention group
Group type: COMPARATOR
Intervention: DNA or rAd5 vaccine alone
Number of subjects: 0
Study 20126394 — intervention group
Group type: EXPERIMENTAL
Intervention: rAd5 boosting
Number of subjects: 0
Study 20126394 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-elicited CD4(+) and CD8(+) T-cells
Number of subjects: 0
Study 20126394 — intervention group
Group type: EXPERIMENTAL
Intervention: Epitopes in Gag and Env
Number of subjects: 0
Study 20127732 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose silybin-phytosome (13 g daily for 14-31 days, mean 20 days)
Number of subjects: 12
Study 20127732 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study 20127939 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent body fat
Number of subjects: 22
Study 20127939 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent adipose tissue
Number of subjects: 22
Study 20128887 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strategy directed towards health-care professionals and patients including training on Clinical Practice Guidelines (CPG) and health education.
Number of subjects: 801
Study 20128887 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice (control group).
Number of subjects: 801
Study 20129546 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 436
Study 20129546 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 436
Study 20129549 — intervention group
Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus-eluting stent (ZES)
Number of subjects: 8314
Study 20129551 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES) implantation
Number of subjects: 30
Study 20129555 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 1580
Study 20129555 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 1580
Study 20129555 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention minimum stent area (MSA) for PES
Number of subjects: 1580
Study 20129555 — intervention group
Group type: COMPARATOR
Intervention: Post-intervention minimum stent area (MSA) for BMS
Number of subjects: 1580
Study 20129555 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention IVUS MSA
Number of subjects: 1580
Study 20130244 — intervention group
Group type: EXPERIMENTAL
Intervention: SC-EPOCH-RR
Number of subjects: 33
Study 20131111 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMI alarm activated by prehospital emergency physicians
Number of subjects: 196
Study 20131111 — intervention group
Group type: COMPARATOR
Intervention: No intervention (before implementation of the STEMI alarm)
Number of subjects: 196
Study 20133268 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily efavirenz 600 mg and lamivudine 300 mg with enteric-coated didanosine 400 mg (DART I)
Number of subjects: 0
Study 20133268 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily efavirenz 600 mg and lamivudine 300 mg with extended-release stavudine 100 mg (DART II)
Number of subjects: 0
Study 20133268 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily efavirenz-based antiretroviral therapy
Number of subjects: 0
Study 20133465 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen administration after GnRH antagonist and graded doses of GnRH
Number of subjects: 16
Study 20133895 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacetuzumab (SGN-40), 4 mg/kg and 12 mg/kg/week
Number of subjects: 44
Study 20133895 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacetuzumab (SGN-40), 12 mg/kg/week
Number of subjects: 44
Study 20133895 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacetuzumab (SGN-40) with steroid pre-medication
Number of subjects: 44
Study 20133895 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacetuzumab (SGN-40)
Number of subjects: 44
Study 20136164 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibric acid + low-dose statin
Number of subjects: 586
Study 20136164 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibric acid + moderate-dose statin
Number of subjects: 586
Study 20136164 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibric acid + low- or moderate-dose statin
Number of subjects: 586
Study 20136164 — intervention group
Group type: COMPARATOR
Intervention: Control: Low-dose statin monotherapy
Number of subjects: 586
Study 20136164 — intervention group
Group type: COMPARATOR
Intervention: Control: Moderate-dose statin monotherapy
Number of subjects: 586
Study 20139093 — intervention group
Group type: EXPERIMENTAL
Intervention: CRLF2 rearrangements
Number of subjects: 207
Study 20139093 — intervention group
Group type: COMPARATOR
Intervention: No CRLF2 rearrangements
Number of subjects: 207
Study 20139439 — intervention group
Group type: EXPERIMENTAL
Intervention: PCWP (pulmonary capillary wedge pressure)
Number of subjects: 29
Study 20139439 — intervention group
Group type: EXPERIMENTAL
Intervention: LA volume (left atrial volume)
Number of subjects: 29
Study 20139439 — intervention group
Group type: EXPERIMENTAL
Intervention: E/e' (Doppler index for LV filling)
Number of subjects: 29
Study 20139439 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analysis for PCWP, LA volume index, and E/e'
Number of subjects: 29
Study 20139774 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/m cyclophosphamide
Number of subjects: 13
Study 20139774 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/m cyclophosphamide
Number of subjects: 13
Study 20139774 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg/m cyclophosphamide
Number of subjects: 13
Study 20139774 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (150 and 250 mg/m)
Number of subjects: 13
Study 20142198 — intervention group
Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus-eluting coronary stent
Number of subjects: 0
Study 20142198 — intervention group
Group type: COMPARATOR
Intervention: Driver bare metal stent (BMS)
Number of subjects: 0
Study 20142553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreous ranibizumab (lucentis)
Number of subjects: 0
Study 20142724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg plus gefitinib 250 mg
Number of subjects: 42
Study 20145390 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic-stage ischemic stroke patients
Number of subjects: 2069
Study 20145390 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, modified Rankin Scale (mRS), duration after onset, Japan Stroke Scale Depression score (JSS-D)
Number of subjects: 2069
Study 20145390 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative factors for PCS
Number of subjects: 2069
Study 20145390 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative factors for MCS
Number of subjects: 2069
Study 20145731 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (150, 200, or 300 minutes/week)
Number of subjects: 397
Study 20145731 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 397
Study 20145731 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prescribed exercise)
Number of subjects: 397
Study 20147717 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy (42.5 Gy in 16 fractions over 22 days)
Number of subjects: 1234
Study 20147717 — intervention group
Group type: COMPARATOR
Intervention: Standard radiation therapy (50.0 Gy in 25 fractions over 35 days)
Number of subjects: 1234
Study 20149262 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Sorafenib (400 mg, p.o., twice a day for 12 months)
Number of subjects: 30
Study 20149262 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy of 3DCRT/IMRT and TACE
Number of subjects: 30
Study 20149262 — intervention group
Group type: COMPARATOR
Intervention: TACE combined with radiotherapy
Number of subjects: 30
Study 20149736 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously monthly (every 28 days), with loading doses on days 8 and 15 of month 1.
Number of subjects: 37
Study 20150292 — intervention group
Group type: EXPERIMENTAL
Intervention: MD-Logic Artificial Pancreas (MDLAP) System
Number of subjects: 7
Study 20150297 — intervention group
Group type: EXPERIMENTAL
Intervention: Former intensive insulin treatment
Number of subjects: 1186
Study 20150297 — intervention group
Group type: COMPARATOR
Intervention: Former conventional insulin treatment
Number of subjects: 1186
Study 20151726 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IV esomeprazole (80 mg infusion over 30 min, then 8 mg/hour for 71.5 hours)
Number of subjects: 0
Study 20151726 — intervention group
Group type: COMPARATOR
Intervention: No-IV esomeprazole treatment
Number of subjects: 0
Study 20151726 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IV esomeprazole
Number of subjects: 0
Study 20151726 — intervention group
Group type: COMPARATOR
Intervention: No-IV esomeprazole
Number of subjects: 0
Study 20152220 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) with Angiotensin-Converting Enzyme Inhibitors (ACEIs)
Number of subjects: 0
Study 20152220 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) with Angiotensin Receptor Blockers (ARBs)
Number of subjects: 0
Study 20152220 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) with ACEI or ARB
Number of subjects: 0
Study 20153880 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated elastic compression stockings
Number of subjects: 0
Study 20153880 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 20153880 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic Low Molecular Weight Heparin (LMWH)
Number of subjects: 0
Study 20153880 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted-dose of LMWH through pregnancy and postpartum
Number of subjects: 0
Study 20154700 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasectomy by epithelial curettage with Vas-X
Number of subjects: 12
Study 20155590 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home unattended polysomnography
Number of subjects: 88
Study 20155590 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine toxicology on polysomnographic nights
Number of subjects: 88
Study 20155590 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography signal quality and overall study success rates
Number of subjects: 88
Study 20156060 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (4-week intensification)
Number of subjects: 10
Study 20156608 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency (RF) ablation of the PV antrum, parasympathetic ganglionated plexi, and ligament of Marshall
Number of subjects: 50
Study 20156608 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 50
Study 20156608 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative management (medical therapy)
Number of subjects: 50
Study 20156960 — intervention group
Group type: EXPERIMENTAL
Intervention: MREG sites (Minority Recruitment Enhancement Grants)
Number of subjects: 602
Study 20156960 — intervention group
Group type: COMPARATOR
Intervention: Comparison sites (nonawarded sites)
Number of subjects: 602
Study 20157038 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 20157136 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants (90.5% of patients received anticoagulants)
Number of subjects: 844
Study 20157136 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulants (control group not explicitly mentioned)
Number of subjects: 844
Study 20157193 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation, medical management, or bilateral adrenalectomy
Number of subjects: 112
Study 20157193 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Cushing syndrome (CS)
Number of subjects: 112
Study 20157193 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous resolution of Cushing syndrome
Number of subjects: 112
Study 20160046 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir (individualized single doses based on body weight ranging from 25 to 175 mg)
Number of subjects: 18
Study 20160046 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 18
Study 20160160 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA guideline risk stratification
Number of subjects: 161808
Study 20160169 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable leadless cardiac monitor (ICM)
Number of subjects: 247
Study 20163987 — intervention group
Group type: EXPERIMENTAL
Intervention: MTD gemcitabine (1000 mg/m² on days 1 and 8), metronomic capecitabine (500 mg/m² twice a day on days 1-14), and sorafenib (400 mg twice a day on days 1-21) for six cycles followed by sorafenib monotherapy if clinical benefit was maintained.
Number of subjects: 40
Study 20163987 — intervention group
Group type: EXPERIMENTAL
Intervention: MTD gemcitabine, metronomic capecitabine, and sorafenib regimen.
Number of subjects: 40
Study 20163987 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to the treatment regimen.
Number of subjects: 40
Study 20167848 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination (50 x 10(6) mature dendritic cells pulsed with autologous tumor lysate and KLH)
Number of subjects: 10
Study 20170786 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium score (CS) = 0
Number of subjects: 291
Study 20170786 — intervention group
Group type: EXPERIMENTAL
Intervention: No calcium
Number of subjects: 291
Study 20170786 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally occluded vessels
Number of subjects: 291
Study 20172911 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Task Force Criteria for ARVC/D diagnosis
Number of subjects: 0